Loading...

Farshid Dayyani

Title(s)Clinical Professor, Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Peritoneal carcinomatosis in gastric cancer: Are Hispanics at higher risk? J Surg Oncol. 2020 Sep 09. Choi AH, Ji L, Babcock B, Ramos V, Kwong MLM, Morgan JW, Selleck MJ, Langridge WHR, DeLeon M, Wall NR, Lum S, Pigazzi A, Dayyani F, Senthil M. PMID: 32901938.
      View in: PubMed   Mentions:    Fields:    
    2. A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. Tumour Biol. 2020 Sep; 42(9):1010428320958603. Muley T, Zhang X, Holdenrieder S, Korse CM, Zhi XY, Molina R, Liu Z, Hartmann G, van den Heuvel MM, Qian K, Marrades R, Engel C, He Y, Wehnl B, Dayyani F, Herth F. PMID: 32964798.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. J Natl Compr Canc Netw. 2020 Jul; 18(7):798-804. Demisse R, Damle N, Kim E, Gong J, Fakih M, Eng C, Oesterich L, McKenny M, Ji J, Liu J, Louie R, Tam K, Gholami S, Halabi W, Monjazeb A, Dayyani F, Cho M. PMID: 32634770.
      View in: PubMed   Mentions:    Fields:    
    4. Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncoimmunology. 2020 Jun 10; 9(1):1773200. Zhang T, Pabla S, Lenzo FL, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Giamo V, Andreas J, Wang Y, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Gupta R, Zhu J, Labriola M, McCall S, George DJ, Ghatalia P, Dayyani F, Edwards R, Park MS, Singh R, Jacob R, George S, Xu B, Zibelman M, Kurzrock R, Morrison C. PMID: 32923131.
      View in: PubMed   Mentions:
    5. Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategies-a single institution experience. J Gastrointest Oncol. 2020 Apr; 11(2):411-420. Hoang T, Park M, Hiyama D, Dayyani F. PMID: 32399281.
      View in: PubMed   Mentions:
    6. Gene mutations distinguishing gastric from colorectal and esophageal adenocarcinomas. J Gastrointest Oncol. 2020 Feb; 11(1):45-54. Hoang T, Ganesan AK, Hiyama D, Dayyani F. PMID: 32175104.
      View in: PubMed   Mentions:
    7. Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions. J Oncol Pract. 2019 08; 15(8):421-428. Mar N, Dayyani F. PMID: 31404517.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist. 2019 11; 24(11):1462-1468. Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J. PMID: 31249137.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. Lung Cancer. 2019 04; 130:194-200. Muley T, He Y, Rolny V, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Meister M, Herth FJ, Dayyani F. PMID: 30885344.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol. 2018; 2018. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. PMID: 30148248.
      View in: PubMed   Mentions:
    11. Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer. Tumour Biol. 2018 Apr; 40(4):1010428318772202. Holdenrieder S, Molina R, Qiu L, Zhi X, Rutz S, Engel C, Kasper-Sauer P, Dayyani F, Korse CM. PMID: 29701125.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC). Lung Cancer. 2018 06; 120:46-53. Muley T, Rolny V, He Y, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Dienemann H, Meister M, Herth FJ, Dayyani F. PMID: 29748014.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis. Br J Cancer. 2017 Apr 11; 116(8):1037-1045. Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, Dayyani F. PMID: 28278517.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    14. Letter in response to: Identifying risk in the use of tumor markers to improve patient safety. Clin Chem Lab Med. 2016 12 01; 54(12):e383-e384. Dayyani F, Morgenstern D. PMID: 27467754.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Clinically Meaningful Use of Blood Tumor Markers in Oncology. Biomed Res Int. 2016; 2016:9795269. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. PMID: 28042579.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    16. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis. Int J Gynecol Cancer. 2016 11; 26(9):1586-1593. Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, Schlumbrecht M. PMID: 27540691.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    17. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer. 2016 09 06; 16:721. Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG. PMID: 27599544.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    18. TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia. Leuk Res. 2016 09; 48:46-56. Shin TH, Brynczka C, Dayyani F, Rivera MN, Sweetser DA. PMID: 27486062.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    19. In Response to "Serum Tumor Marker Use in Patients With Advanced Solid Tumors". J Oncol Pract. 2016 Mar; 12(3):273-4. Dayyani F, Morgenstern D, Holdenrieder S. PMID: 26837562.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol. 2014 Aug; 74(2):379-87. Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD. PMID: 24939212.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    21. Management of advanced primary urethral carcinomas. BJU Int. 2014 Jul; 114(1):25-31. Dayyani F, Hoffman K, Eifel P, Guo C, Vikram R, Pagliaro LC, Pettaway C. PMID: 24447439.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    22. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 2013 Oct 01; 133(7):1536-46. Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. PMID: 23526299.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    23. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate. 2013 Jun; 73(9):979-85. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. PMID: 23371521.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    24. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One. 2012; 7(12):e51189. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. PMID: 23300537.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    25. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 01; 19(3):657-67. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. PMID: 23251002.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansAnimalsCells
    26. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013 May; 189(5):1656-61. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. PMID: 23159581.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    27. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol. 2013 Oct; 31(7):1171-7. Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. PMID: 22534087.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    28. Transcript profiling of CD16-positive monocytes reveals a unique molecular fingerprint. Eur J Immunol. 2012 Apr; 42(4):957-74. Frankenberger M, Hofer TP, Marei A, Dayyani F, Schewe S, Strasser C, Aldraihim A, Stanzel F, Lang R, Hoffmann R, Prazeres da Costa O, Buch T, Ziegler-Heitbrock L. PMID: 22531920.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCellsCTClinical Trials
    29. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 2011 Dec; 20(12):1677-84. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. PMID: 22035268.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    30. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011 Nov 16; 103(22):1665-75. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. PMID: 21917607.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    31. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol. 2011 Jul; 86(7):546-9. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. PMID: 21509801.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    32. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 2011 Jun 01; 128(11):2545-61. Jin JK, Dayyani F, Gallick GE. PMID: 21365645.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimals
    33. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011 Jan 01; 117(1):110-5. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. PMID: 20803607.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    34. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010 Jun 29; 2:15. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. PMID: 20587061.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCells
    35. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010 May 01; 116(9):2174-9. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. PMID: 20162709.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    36. HIV-associated multicentric Castleman's disease. Am J Hematol. 2008 Jun; 83(6):498-503. Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ. PMID: 18260115.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    37. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 2008 May 01; 111(9):4716-22. Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. PMID: 18299447.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    38. Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. Blood. 2008 Apr 15; 111(8):4338-47. Dayyani F, Wang J, Yeh JR, Ahn EY, Tobey E, Zhang DE, Bernstein ID, Peterson RT, Sweetser DA. PMID: 18258796.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    39. Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci. 2007 Oct; 334(4):317-9. Dayyani F, Pantanowitz L, Sandridge TG, Sullivan RJ, Dezube BJ. PMID: 18030193.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    40. Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia. Genes Chromosomes Cancer. 2005 Nov; 44(3):279-91. Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, Daly SB. PMID: 16015647.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    41. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood. 2004 Sep 15; 104(6):1825-32. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. PMID: 15161667.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    42. Impact of type-I-interferon on monocyte subsets and their differentiation to dendritic cells. An in vivo and ex vivo study in multiple sclerosis patients treated with interferon-beta. J Neuroimmunol. 2004 Jan; 146(1-2):176-88. Then Bergh F, Dayyani F, Ziegler-Heitbrock L. PMID: 14698861.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    43. Autologous stem-cell transplantation restores the functional properties of CD14+CD16+ monocytes in patients with myeloma and lymphoma. J Leukoc Biol. 2004 Feb; 75(2):207-13. Dayyani F, Joeinig A, Ziegler-Heitbrock L, Schmidmaier R, Straka C, Emmerich B, Meinhardt G. PMID: 14576364.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    44. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol. 2003 Sep; 122(6):892-9. Meinhardt G, Dayyani F, Jahrsdörfer B, Baumgart J, Emmerich B, Schmidmaier R. PMID: 12956758.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    45. Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes. J Leukoc Biol. 2003 Jul; 74(1):33-9. Dayyani F, Belge KU, Frankenberger M, Mack M, Berki T, Ziegler-Heitbrock L. PMID: 12832440.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    46. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002 Apr 01; 168(7):3536-42. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L. PMID: 11907116.
      View in: PubMed   Mentions: 251     Fields:    Translation:HumansCells
    47. Selective mobilization of CD14(+)CD16(+) monocytes by exercise. Am J Physiol Cell Physiol. 2000 Sep; 279(3):C578-86. Steppich B, Dayyani F, Gruber R, Lorenz R, Mack M, Ziegler-Heitbrock HW. PMID: 10942707.
      View in: PubMed   Mentions:
    Farshid's Networks
    Concepts (313)
    Derived automatically from this person's publications.
    _
    Co-Authors (12)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _